Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease

[1]  A. Schambach,et al.  Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML , 2016, Molecular therapy. Methods & clinical development.

[2]  J. Medin,et al.  Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. , 2016, Bioanalysis.

[3]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[4]  L. Naldini,et al.  Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy , 2015, Molecular therapy. Methods & clinical development.

[5]  F. Tsai,et al.  Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[6]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[7]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[8]  M. Gelb,et al.  Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. , 2013, The Journal of pediatrics.

[9]  J. Medin,et al.  Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways , 2013, Virology Journal.

[10]  K. Ihara,et al.  Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study , 2013, Journal of Human Genetics.

[11]  Thomas P. Mechtler,et al.  Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  J. Medin,et al.  Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  N. Socci,et al.  Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data , 2012, Genes, chromosomes & cancer.

[14]  J. Medin,et al.  Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes , 2012, Gene Therapy.

[15]  Manesh R. Patel,et al.  Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry , 2009, Genetics in Medicine.

[16]  Y. Chien,et al.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.

[17]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[18]  P. Elliott,et al.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa , 2007, Heart.

[19]  J. Charrow,et al.  Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. , 2007, Journal of the American Society of Nephrology : JASN.

[20]  G J Murray,et al.  Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells , 2007, Gene Therapy.

[21]  R. Finkel,et al.  Agalsidase-Beta Therapy for Advanced Fabry Disease , 2007, Annals of Internal Medicine.

[22]  J. Medin,et al.  Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[23]  S. Feriozzi,et al.  Enzyme replacement therapy and renal function in 201 patients with Fabry disease. , 2006, Clinical nephrology.

[24]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[25]  G. Houge,et al.  [Fabry disease--a diagnostic and therapeutic challenge]. , 2005, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[26]  H. Kayserili,et al.  Mutations in the AHI1 gene, encoding jouberin, cause Joubert syndrome with cortical polymicrogyria. , 2004, American journal of human genetics.

[27]  A. Poeppl,et al.  Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Walsh,et al.  Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome , 2004, Nature Genetics.

[29]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[30]  R. Desnick,et al.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. , 2004, American journal of human genetics.

[31]  C. Eaves,et al.  Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. , 2004, Blood.

[32]  Manfred Gessler,et al.  The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. , 2004, Genes & development.

[33]  F. Baehner,et al.  Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study , 2003, Journal of Inherited Metabolic Disease.

[34]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[35]  R. Colvin,et al.  Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. , 2002, Kidney international.

[36]  L. Girard,et al.  Ahi-1, a Novel Gene Encoding a Modular Protein with WD40-Repeat and SH3 Domains, Is Targeted by the Ahi-1 and Mis-2 Provirus Integrations , 2002, Journal of Virology.

[37]  C. Eng,et al.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.

[38]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[39]  R. Brady,et al.  Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Kulkarni,et al.  Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Sakuraba,et al.  Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells. , 1999, Human gene therapy.

[42]  R. Brady,et al.  Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. , 1999, Human gene therapy.

[43]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[44]  I. Pastan,et al.  alpha-Galactosidase A deficient mice: a model of Fabry disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Brady,et al.  Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  I. Pastan,et al.  Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. , 1995, Human gene therapy.

[47]  M. Kozak.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. , 1987, Nucleic acids research.

[48]  R. Brady,et al.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.

[49]  R. Giugliani,et al.  Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects. , 2013, JIMD reports.

[50]  A. Rolfs,et al.  Newborn screening for lysosomal storage disorders in hungary. , 2012, JIMD reports.